Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
Maxwell Z Price1, Richard L Price2
1Hackensack Meridian School of Medicine, Nutley, NJ, 07110, USA. mzp2103@columbia.edu.
CNS Drugs
|July 10, 2023
Summary
Patients with combined ADHD showed significant symptom improvement switching from atomoxetine to viloxazine ER (VER). VER demonstrated greater efficacy and tolerability for both inattention and hyperactivity/impulsivity in pediatric and adult ADHD patients.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroscience
Background:
- Psychostimulants and alpha-2 agonists are common ADHD treatments with limitations.
- Atomoxetine and viloxazine ER (VER) are used for combined ADHD, but insurers often mandate atomoxetine trials first.
- This study addresses the need to evaluate VER as an alternative to atomoxetine for combined ADHD.
Purpose of the Study:
- To determine if pediatric and adult patients with combined ADHD experience symptom improvement after switching from atomoxetine to VER.
- To compare the efficacy and tolerability of VER versus atomoxetine in treating ADHD symptoms.
Main Methods:
- A retrospective review of 50 pediatric and adult patients with combined ADHD was conducted.
- Patients switched from atomoxetine to flexibly titrated VER after a washout period.
- ADHD symptoms were assessed using ADHD-RS-5 and AISRS scales before and after treatments.
Main Results:
- Patients showed significantly greater improvement in both inattention and hyperactivity/impulsivity on VER compared to atomoxetine.
- 86% of patients reported a positive response to VER within 2 weeks, versus 14% on atomoxetine.
- VER had better tolerability, with only 4% discontinuing due to side effects compared to 36% for atomoxetine.
Conclusions:
- Extended-release viloxazine (VER) offers rapid improvement in ADHD symptoms for patients with combined type ADHD.
- VER demonstrates superior efficacy and tolerability compared to atomoxetine in this patient population.
- VER may be a valuable alternative for patients with combined ADHD who have an inadequate response or intolerance to atomoxetine.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.8K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.4K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
132
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
132
01:23Antidepressant Drugs: MAOIs and Other Agents
275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
01:25Antidepressant Drugs: Overview
589
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
589
01:26Anxiolytic Drugs: Overview
368
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
368
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349